Immunotherapy against amyloid-beta (Aβ) may improve rodent cognitive function by reducing amyloid neuropathology and is being validated in clinical trials with positive preliminary results. However, for a complete understanding of the direct and long-term immunization responses in the aged patient, and also to avoid significant side effects, several key aspects remain to be clarified. Thus, to investigate brain Aβ clearance and Th2 responses in the elderly, and the reverse inflammatory events not found in the immunized rodent, better Alzheimer's disease (AD) models are required. In the aged familiar canine with a cognitive dysfunction syndrome (CDS) we describe the rapid effectiveness and the full safety profile of a new active vaccine candidate for human AD prevention and treatment. In these aged animals, besides a weak immune system, the antibody response activated a coordinated central and peripheral Aβ clearance, that rapidly improved their cognitive function in absence of any side effects. Our results also confirm the interest to use familiar dogs to develop innovative and reliable therapies for AD.
Rapid improvement of canine cognitive dysfunction with immunotherapy designed for Alzheimer's disease
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INTRODUCTION
Alzheimer's disease is characterized by the presence of intracellular neurofibrillary tangles and extracellular Aβ plaques, with Aβ monomers and oligomers resulting from the amyloid precursor protein (APP) processing [1] . In the AD amyloid hypothesis, the extracellular accumulation of soluble Aβ peptide leads to CNS formation of soluble oligomers, fibrils and amyloid plaques, and the distribution between brain and blood compartments, reflects the imbalance between Aβ production and clearance [2] . The Aβ fibril formation is currently considered a dynamic and reversible process, as Aβ fibrils are continuously dissolving and reforming [3] . Because AD stage severity correlates more with soluble Aβ brain levels than with Aβ plaque abundance [2, 4, 5] , the amyloid monomers and oligomers are considered to be more toxic [1, 6] .
Blockade of the AD course at early phases through different immunological anti-Aβ strategies to interfere the amyloid peptide homeostasis have given promising results.
For example, active immunization targeting Aβ peptide in AD Tg mice has demonstrated striking reductions in Aβ deposition and reduction of behavioral impairments [7] [8] [9] , and the same was observed in human beings [10] . However, significant questions remain to be answered for a full understanding of the direct and long-term immunization responses, and to avoid significant side effects in trials conducted with human patients. Thus, the development of new active vaccines inducing both Aβ clearance and only Th2 responses in good AD models remain key issues to be solved [11, 12] . Dog with cognitive dysfunction syndrome (CDS) is considered a suitable model to address these innovative therapies [13] , because it spontaneously expresses several markers associated with the underlying pathology of sporadic AD. Control aged dog (over 7-8 years) is also considered quite unique to elucidate the amyloid hypothesis, since its CNS Aβ peptide accumulation is responsible for neuronal dysfunction and deregulation of the same specific cortical subsets of interneurons described in the aged human [14] [15] [16] [17] . In addition, these aged animals also bring multiple druggable targets for the identification of novel disease-modifying agents to interfere natural Aβ production, aggregation, clearance or the associated neurotoxic effects [18, 19] .
Compared to the aged housed dog, some familiar dogs develop geriatric behavioral changes that give rise to a specific CDS, also known as canine counterpart of senile dementia of the Alzheimer's type. Because of their many common hallmarks, CDS is presently considered a model of choice for Mild Cognitive Impairment (MCI) and AD research [15, 20, 21] , and, in particular, for the development of anti-Aβ immunotherapy [13, 22, 23] . Diagnosed of graded cognitive dysfunctions by practicing neurology veterinarians, these animals are systematically and easily classified into wellcharacterized homogenous groups with no variation due to their breed (including sex, size and genetic background) or familiar life conditions [24] [25] [26] . In this study, we took advantage of this familiar model to investigate the effectiveness and safety of new active amyloid vaccines. This study is aimed at increasing our understanding of how immunomodulation supports CNS Aβ clearance, how it relates to cognitive improvement, and how it supports a safe and effective new AD immunotherapy. 
MATERIAL AND METHODS
Vaccine preparation
Animals
To select the vaccine of major interest, 6 adult female New Zealand White rabbits weighing between 1.5-2 kg at the beginning of the study were immunized with one of the 3 vaccines following the protocol selected for dogs. They were kept on a 12h
light/12 h dark cycle and housed with free access to food and water.
The safety and immunization studies were performed in 36 dogs (12 housed beagle dogs + 24 familiar dogs). The 12 male housed beagle dogs from Harlan laboratories (Gannat, France), with an age ranging between 2 and 8 years at the beginning of the study, were housed in groups of three in 1.85m wide x 3m large buildings, and were daily fed with 340gr of Hill's canine adult food. 
Screening study
For the screening study all the 36 dogs were classified following their age and cognitive status in Adult Control dogs (AC), OC and LCD or SCD (Table 1) .
For each dog, a biochemical and hematological profile was regularly performed that also included Aβ levels in blood and Cerebrospinal Fluid (CSF). The albumin coefficient reflecting the Blood-Brain-Barrier (BBB) integrity [28] was also calculated. All animals were also monitored for adverse reactions and the vaccine puncture zone was periodically revised.
Immunization study
Following the recommendation of the Ethics Committee, the use of healthy adult and old familiar dogs as control animals for the immunization study had to be avoided as the following 21 dogs were considered sufficient to obtain reliable data: 9 housed beagle dogs as control group and 12 CDS familiar dogs, with the acceptation of their owners, as the Case group (Table 1) .
The study was performed over a period of 131 days, with 6 s.c. injections administered during a period of 51 days in the back of the neck (Fig.1 ). 6 housed beagle dogs were immunized with the v3 vaccine (Immunized AC) and 9 dogs CDS dogs were immunized (Immunized CDS). The remaining 3 housed adult beagles and 3 familiar dogs were included in the Placebo group (Table 1) . Cognitive follow-up of all CDS animals was performed on a double blind basis at days 31, 51 and 131, by the veterinarian and the pet's owner, and blood and CSF parameters were regularly evaluated ( Fig.1 ).
Blood and CSF extraction
Serum and plasma were obtained after 5ml blood extraction from the animal jugular vein every 10 days until day 71, and then at day 131. Once collected in tubes (BD, NJ, USA) containing EDTA for plasma or clotting gel for serum, blood was centrifuged at 3000rpm during 15 minutes, aliquoted and kept at -80ºC until use. CSF was collected under 10mg/kg of sodium thiopental (Thiobarbital, Braun Medical S.A., Spain) intravenous (i.v.) anesthesia. Then, dogs were intubated, and oxygen administered following induction. Monitoring devices were used to control heart rate, blood pressure and blood oxygenation. The dog's coat was clipped and prepared for an aseptic procedure, and CSF collected (1ml/5kg) by cisternal puncture into a sterile glass tube.
Afterwards, it was divided into 0.5ml aliquots and quickly stored at -80°C until use.
Biochemical and hematological analysis
Biochemical parameters were analyzed by spectrophotometry (DIRUI CS-800, RAL, Barcelona, Spain) and hematological parameters were measured by laminar flow impedance (Procyte DX, Barcelona, Spain) ( Table 3 ). The albumin quotient (Qalb) was calculated as the quotient between the albumin CSF (mg/L) and blood (g/L)
concentration. CSF albumin was quantified by immunonephelometry (BN2, Siemens, Marburg, Germany) and serum albumin with the colorimetric bromocresol method (ADVIA 1800, Siemens diagnostic, Marburg, Germany).
Anti-Aβ IgG titration
For the rabbit anti-Aβ IgG titration, a Maxisorb 96 well plate (Nunc, Langenselbold, Samples from each dog were included in the same plate and 3 wells added with TBS-BSA 5% were also used for background. triton-X100-Normal goat serum 5%-BSA 5% as a blocking agent for 2h at RT. Purified primary antibodies were diluted with immunobuffer (PBS-5%-triton-X100-1%NGS-1%BSA) at a correct concentration, or commercial anti-Aβ antibody diluted at 1/100
were added an incubated ON at 4ºC. After 3 washes with PBS, samples were incubated with 1/4000 diluted biotin rabbit anti-dog IgG (Lifespan bioscience, Derio, Inc., NY, USA) and micrographs were taken at 5x and 40x.
Statistical analysis
Kurtosis and skewness moments were calculated to verify the normal distribution of 
RESULTS
The v3 vaccine induces the highest antibody titration in rabbit
To select the vaccine of major interest, an immunization study with v1, v2 and v3 was initially conducted in rabbits. To this end, 6 animals (n=2/group) were immunized with one vaccine following the immunization protocol selected for dogs. Blood samples were also extracted at the same selected time points until day 71, and anti-Aβ IgG measured. All three vaccines induced immunization, however the v3 composition gave the highest anti-Aβ IgG titration at day 71 (Fig. 3A) . No side effect was detected in any animal.
Dogs with light cognitive deficits have increased levels of plasma protein, platelets and Aβ levels
When the 24 familiar dogs were evaluated at the beginning of the study (day 0) with our cognitive test, CDS was identified in 14 animals that presented light cognitive deficits (LCD, n=10) or severe cognitive deficits (SCD, n=4) ( Table 2 ). The remaining 10 animals classified as control were distributed with the 12 housed beagle dogs between the Adult Control group (AC, < 8 years, n=14) and the Old Control group (OC, n=8).
During the whole study, all 16 biochemical and hematological parameters were found in the normal range in all animals. However, in the CDS group plasma protein levels and platelets was always higher and reticulocyte counts lower (p=0.004, 0.001 and 0.002, respectively) (Data not shown).
LCD dogs presented the highest Aβ 40 plasma level (p=0.029) ( Fig. 2A) , and in all groups Aβ 42 was lower than the plasma detection limit. In CSF, Aβ 40 levels remained stable with aging and cognitive dysfunction, while Aβ 42 levels only increased in the LCD dogs (p=0.018) (Fig. 2B,C) (Fig. 2D) .
Cognitive improvement of v3 immunized CDS dogs is accompanied by an increased plasma/CSF Aβ ratio
The cognitive test was performed at days 0, 31, 51 and 131 in all dogs included in the v3 immunization study. At day 31 the immunized CDS dogs presented a 30% lower score (p=0.027) (Fig. 3B ) that was maintained until day 51. At this day, a greater reduction of the score was observed in SCD dogs (45%, p=0.010) than in LCD ones (25%, p=0.043). A tendency to decrease was found in placebo animals, probably due to a closer and more frequent owner and veterinarian care. Due to a failing of several owner visits at the end of the study, only two immunized dogs could be evaluated until day 131. Compared to days 51, 31 and 0, both animals gave a lower score (Score values=11 and 9).
To evaluate the molecular response to v3 immunization, all 16 hematological and biochemical blood parameters, as well as the blood and CSF Aβ and anti-Aβ 40 IgG levels, were measured during the whole immunization period.
Only the Alkaline Phosphatase (AP) value was not within the normal range in some familiar dogs (Table 3 ). Higher AP levels at days 71 and 130 (p=0.023 and 0.049, respectively) were detected in immunized CDS dogs compared to the placebo group, and were probably related to the irregular familiar feeding habits.
Qalb ratio remained similar in the AC and CDS groups during the whole study (Data not shown).
In the v3 immunized AC dogs, Aβ 40 plasma levels presented a tendency to increase until day 41. The same tendency, but with a larger variability, was observed until day 51 in the v3 immunized CDS group (Fig. 4A ). When compared with placebo, immunized AC dogs presented a similar Aβ 40 CSF level between day 0 and 131, while Aβ 42 value peaked at day 131 (p=0.034). In the immunized CDS group, Aβ 40 CSF levels presented a tendency to decrease (Fig. 4B) , and Aβ 42 levels were lower at day 51 (p=0.049) (Fig. 4C) . When the ratio between plasma and CSF Aβ was obtained, a major tendency to increase was found in the immunized CDS dogs compared to placebo and AC immunized animals (Fig. 4D ). When the analysis was performed with the immunized LCD1, the increasing values reached significant differences between LCD1 immunized dogs and Placebo and AC animals at day 51 (p=0.0211) (Fig. 4H ).
Significant plasma and CSF changes of the anti-Aβ 40 IgG levels were observed in all v3
immunized dogs during the whole follow-up,. Thus, in the immunized AC group, the anti-Aβ 40 IgG serum levels reached a peak at day 31 and remained increased until day 51 when compared to its pre-immune (p=0.0042) and Placebo group values (p=0.0079); at day 131 it returned to baseline value. Anti-Aβ 40 IgG serum levels peaked at day 71 in immunized CDS dogs, higher that their pre-immune (p=0.0078) and the Placebo group values (p=0.0022) (Fig. 4E) , being back to baseline at day 131. CSF Anti-Aβ 40 IgG of immunized AC dogs were increased at day 51 compared to preimmune (p=0.0042) and placebo values (p=0.0078). CDS animals showed a similar tendency, but with lower levels (Fig. 4F) . Both AC and CDS groups presented a positive correlation between serum and CSF anti-Aβ 40 IgG levels (r 2 =0.53, p=0.0013) (Fig. 4I) . However, only in the immunized CDS group and during the whole study, the anti-Aβ 40 IgG and Aβ 40 plasma ratio was 1/25, with a positive and linear correlation during the whole study (r 2 =0.362, p=0.0049) (Fig. 4G ).
Anti-Aβ40 IgG from v1, v2 or v3 immunized rabbits and v3 immunized dogs recognize human amyloid plaques
In cerebral cortex of human with AD, immunohistochemistry with plasma anti-Aβ IgG isolated from the different immunized rabbits and dogs specifically stained amyloid plaques but not vessels. Purified antibodies from serum of v1 and v3 immunized rabbits presented a strong immunodetection of diffuse and core amyloid plaques, but the ones from v2 immunized rabbits only detected diffuse plaques (Fig. 5B, C, D) .
Purified dog anti-Aβ IgG presented a stronger staining of diffuse plaques than of core plaques (Fig. 5F, G) .
DISCUSSION
Our data reinforce the CDS dog as a good natural AD model and fosters immunotherapy for Aβ pathologies, like canine CDS or human AD. Amyloid pathology associated with canine cognitive dysfunction presents a positive correlation between plaque maturation and degree of cognitive dysfunction [24, 29] . In this study, CDS familiar dogs were classified based on their cognitive dysfunction degree and age in order to identify specific biomarkers of amyloid homeostasis of help for AD.
Firstly, the higher values of plasmatic proteins and lower reticulocyte number found in the LCD1 group may reflect the oxidative damage and inflammatory processes involved in the first stages of the disease. Initial amyloid deposition, related to oxidative stress and inflammation [17, 30] , might then be associated with alterations of hematological parameters present in aging and oxidative damage [31] . Secondly, we also found higher plasma levels of Aβ 40 in the LCD1 group, which would indicate a relationship between plasma Aβ 40 and cognitive dysfunction. This hypothesis, approached in rodents and dogs with conflicting results [32] [33] [34] , is difficult to validate due to the Aβ hydrophobic properties and its important binding to plasma proteins, such as albumin, that cause analytical interferences and variability.
Similarly, although no relationship has been established between Aβ plasma levels and BBB permeability, several studies in human beings, dogs and rodents describe an increased BBB permeability with aging [35, 36] . However, besides the association between BBB permeability and inflammatory diseases [37] [38] [39] [40] , no correlation has been established between BBB permeability and cognitive dysfunction [39, 41] . Our results evidence that BBB permeability is only increased in aging healthy dogs, and remains stable in CDS dogs, similar to young matched animals, reflecting a lack of BBB alteration associated with cognitive dysfunction.
In fact, our findings reinforce the familiar dog to help decipher the early events of the diffuse Aβ plaque maturation and explain its relationship with human cognitive dysfunction [13] . For example, together with differences in platelet levels in the LCD1 group, a comparison between these dogs and the human MCI [42] , specifically with amnesic MCI, in which the disease progress to AD might bring new advances.
Finally, we found no correlation between CSF Aβ 42 and cognitive dysfunction, and only higher Aβ 42 levels in the LCD group that could be used as a marker of early CDS. CSF Aβ 42 level, a biomarker for AD diagnosis and monitoring correlates negatively with total Aβ load in the brain, and also with cognitive dysfunction stage [43] [44] [45] . On the other hand, our CSF results are similar to those described recently in control housed beagles showing that, between the age of 4 and 16, CSF Aβ 40 remains constant and Aβ 42 presents a slight decrease [14] . However, the lack of data regarding Aβ 42 and Aβ 40 plasma variation makes difficult a further amyloid homeostasis explanation. Different dynamic [3] and Aβ aggregation progression processes [46] [47] [48] [49] may explain these differences with the studies in human beings.
Despite the differences between some CDS and AD biomarkers, we can establish a relationship between canine cognitive dysfunction and age-related amyloid biomarkers.
The dog cognitive improvement associated with changes in several biomarkers verifies the potential of our Aβ vaccine for CDS treatment. Our findings also confirm the interest of immunotherapy to stimulate Aβ peptide clearance across the BBB for a rapid and safe cognitive benefit in CDS dogs. Thus, as early as 30 days after initial v3 immunization, plasma Aβ 40 was increased and both CSF Aβ 40 and Aβ 42 decreased.
This was followed by an increased Aβ plasma/CSF ratio in the LCD1 group at day 51.
In the immunized adult control dogs, plasma Aβ 40 was also increased but remained constant in CSF. Therefore, an Aβ 40 plasma/CSF increased ratio would represent a good marker of plasma clearance.
These modifications in plasma Aβ 40 were accompanied by a 10-fold increased serum anti-Aβ 40 IgG, with a peak at day 71 in CDS animals and at day 51 in adult control dogs. Only in this last group, anti-Aβ 40 IgG was significantly increased in CSF at day 51, with an abundance of 0.01% of serum level, whereas in CDS animals, its increase was not significant. Compared to adult control dogs, the reduced immunogenic response in aged dogs, similar to humans [50] , explain the delay and lower level of their serum IgG peak, and the discrete IgG presence in CSF. Anyway, the interrelationship of the processes taking place in CSF and blood seems to be similar in all groups of animals, as shown by the related temporal changes of amyloid parameters and IgG levels in both compartments to facilitate Aβ clearance. This is of special importance in view of the concern regarding the efficacy of immunotherapy in elderly patients with also a weak immune system [51] .
The plasma anti-Aβ 40 IgG and Aβ 40 ratio of 1/25 was only found in immunized CDS dogs, suggesting the direct formation of antigen-antibody complexes to stimulate the sink effect from CNS to the periphery [52] . A variety of studies performed with different antibodies that recognize N and C terminal Aβ fragments argue for the same mechanism [53, 54] . Because differences in antibody recognition of the Aβ peptide define its ability to cross the BBB, our v3 vaccine includes a variety of peptides that induce an antibody mixture to interact with the N or C Aβ terminal. So, the N-Aβ antibody recognition will mostly take place at the periphery, forming ag-ab complexes for the sink effect. Meanwhile, both N-and C-Aβ antibody recognition will favor the central recognition of Aβ monomers, oligomers and mainly diffuse plaques, due to the maturation affinity process of B cells during the immunization period [55, 56] .
BBB damage is observed in many neuropathologies like AD and its permeability increases with aging. However, the lack of BBB alteration in CDS dogs may be related to the absence of mature plaques, or to LRP1 and RAGE modifications in their function of Aβ clearance [57] [58] [59] . In any case, with immunization, the BBB active Aβ removal would increase and facilitate cognitive improvement.
The v3 vaccine antigen builds a boost of antibodies, together with the possibility of a Bcell response by the C-Aβ epitope [60] . Irregular familiar feeding habits are considered the main cause of the dog higher phosphatase alkaline levels because of its role in the digestion and absorption of fats in the intestinal tract [61] and cannot be related to the immunization. The risk of an inflammatory response was also fully discarded by the clinical follow-up of all animals and the normality of the frequent plasma and CSF analyses.
CONCLUSIONS
In conclusion, we have designed and validated in old dogs with graded cognitive dysfunction and a weak immune system the efficacy and security of a new vaccine considered a good candidate for human AD prevention and treatment. This study also confirms familiar dogs as a good natural model of AD, with the aim of developing innovative and reliable therapies. In these animals, the behavioral, CSF and plasma studies are rapid and easy to perform, and allow to decipher the intrinsic mechanisms involved in Aβ physiopathology. This will shed light on our understanding of human amyloidosis. Total score in the 9 items test: <12= normal; 12-26= light cognitive deficits SCD; >26=severe cognitive 45 
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